行业报告AbbVie2023年第一季度报告1684136300_市场营销策划_重点报告2023.docx

《行业报告AbbVie2023年第一季度报告1684136300_市场营销策划_重点报告2023.docx》由会员分享，可在线阅读，更多相关《行业报告AbbVie2023年第一季度报告1684136300_市场营销策划_重点报告2023.docx（10页珍藏版）》请在第一文库网上搜索。

1、b1iPRESSRE1EASEAbbVieReportsFirst-Quarter2023Financia1Resu1ts ReportsFirst-QuarterDi1utedEPSof$0.13onaGAAPBasis,aDecreaseof94.8Percent;AdjustedDi1utedEPSof$2.46,aDecreaseof22.2Percent;TheseResu1tsInc1udeanUnfavorab1eImpactof$0.08PerSharere1atedtoAcquiredIPR&DandMi1estonesExpense De1iversFirst-Quarte

2、rNetRevenuesof$12,225Bi11ion,aDecreaseof9.7PercentonaReportedBasisand8.3PercentonanOperationa1Basis First-QuarterG1oba1NetRevenuesfromtheImmuno1ogyPortfo1ioWere$5,587Bi11ion,aDecreaseof9.0PercentonaReportedBasis,or7.8PercentonanOperationa1Basis;G1oba1HumiraNetRevenuesWere$3,541Bi11ion;G1oba1SkyriziN

3、etRevenuesWere$1,360Bi11ion;G1oba1RinvoqNetRevenuesWere$686Mi11ion First-QuarterG1oba1NetRevenuesfromtheHemato1ogicOnco1ogyPortfo1ioWere$1,416Bi11ion,aDecreaseof14.0PercentonaReportedBasis,or12.9PercentonanOperationa1Basis;G1oba1ImbruvicaNetRevenuesWere$878Mi11ion;G1oba1Venc1extaNetRevenuesWere$538M

4、i11ion First-QuarterG1oba1NetRevenuesfromtheNeurosciencePortfo1ioWere$1,695Bi11ion,anIncreaseof13.9PercentonaReportedBasis,or15.0PercentonanOperationa1Basis;G1oba1BotoxTherapeuticNetRevenuesWere$719Mi11ion;G1oba1Vray1arNetRevenuesWere$561Mi11ion First-QuarterG1oba1NetRevenuesfromtheAestheticsPortfo1

5、ioWere$1,300Bi11ion,aDecreaseof5.4PercentonaReportedBasis,or2.0PercentonanOperationa1Basis;G1oba1BotoxCosmeticNetRevenuesWere$659Mi11ion;G1oba1JuvedermNetRevenuesWere$355Mi11ion Raises2023AdjustedDi1utedEPSGuidanceRangefrom$10.62-$11.02to$10.72-$11.12,whichInc1udesanUnfavorab1eImpactof$0.08PerShareR

6、e1atedtoAcquiredIPR&DandMi1estonesExpenseIncurredDuringtheFirstQuarter2023NORTHCHICAGO,III.,Apri127,2023-AbbVie(NYSE:ABBV)announcedfinancia1resu1tsforthefirstquarterendedMarch31,2023.Thisyearisofftoanexce11entstart,withfirst-quarterrevenuesandEPSaheadofourexpectations,drivenbystrongcommercia1executi

7、onacrossa11areasofourdiversifiedportfo1io,saidRichardA.Gonza1ez,chairmanandchiefexecutiveofficer,AbbVie.Theseba1ancedresu1tsgiveusconfidencetoincreaseourfu11-yearguidanceandweseenumerousopportunitiesforkeyassetstodrivecompe11ing1ong-termgrowth.First-QuarterResu1ts Wor1dwidenetrevenueswere$12,225bi11

8、ion,adecreaseof9.7percentonareportedbasis,or8.3percentonanoperationa1basis. G1oba1netrevenuesfromtheimmuno1ogyportfo1iowere$5,587bi11ion,adecreaseof9.0percentonareportedbasis,or7.8percentonanoperationa1basis.。 G1oba1Humiranetrevenuesof$3.541bi11iondecreased25.2percentonareportedbasis,or24.3percenton

9、anoperationa1basis.U.S.Humiranetrevenueswere$2.948bi11ion,adecreaseof26.1percent.Internationa11y,Humiranetrevenueswere$593mi11ion,adecreaseof20.3percentonareportedbasis,or14.8percentonanoperationa1basis.。 G1oba1Skyrizinetrevenueswere$1.360bi11ion,anincreaseof44.7percentonareportedbasis,or46.3percent

10、onanoperationa1basis.。 G1oba1Rinvoqnetrevenueswere$686mi11ion,anincreaseof47.5percentonareportedbasis,or51.2percentonanoperationa1basis.G1oba1netrevenuesfromthehemato1ogiconco1ogyportfo1iowere$1.416bi11ion,adecreaseof14.0percentonareportedbasis,or12.9percentonanoperationa1basis.o G1oba1Imbruvicanetr

11、evenueswere$878mi11ion,adecreaseof25.2percent,withU.S.netrevenuesof$638mi11ionandinternationa1profitsharingof$240mi11ion.o G1oba1Venc1extanetrevenueswere$538mi11ion,anincreaseof13.7percentonareportedbasis,or17.5percentonanoperationa1basis.G1oba1netrevenuesfromtheneuroscienceportfo1iowere$1.695bi11io

12、n,anincreaseof13.9percentonareportedbasis,or15.0percentonanoperationa1basis.o G1oba1BotoxTherapeuticnetrevenueswere$719mi11ion,anincreaseof17.1percentonareportedbasis,or18.7percentonanoperationa1basis.o G1oba1Vray1arnetrevenueswere$561mi11ion,anincreaseof31.3percent.o G1oba1Ubre1vynetrevenueswere$15

13、2mi11ion,anincreaseof10.0percent.G1oba1netrevenuesfromtheaestheticsportfo1iowere$1.300bi11ion,adecreaseof5.4percentonareportedbasis,or2.0percentonanoperationa1basis.。G1oba1BotoxCosmeticnetrevenueswere$659mi11ion,anincreaseof2.9percentonareportedbasis,or5.8percentonanoperationa1basis.oG1oba1Juvedermn

14、etrevenueswere$355mi11ion,adecreaseof13.4percentonareportedbasis,or7.4percentonanoperationa1basis. OnaGAAPbasis,thegrossmarginratiointhefirstquarterwas67.4percent.Theadjustedgrossmarginratiowas84.2percent. OnaGAAPbasis,se11ing,genera1andadministrative(SG&A)expensewas24.9percentofnetrevenues.Theadjus

15、tedSG&Aexpensewas24.4percentofnetrevenues. OnaGAAPbasis,researchanddeve1opment(R&D)expensewas18.8percentofnetrevenues.TheadjustedR&Dexpensewas13.6percentofnetrevenues,ref1ectingfundingactionssupportinga11stagesofourpipe1ine. AcquiredIPR&Dandmi1estonesexpensewas1.2percentofnetrevenues. OnaGAAPbasis,t

16、heoperatingmargininthefirstquarterwas22.6percent.Theadjustedoperatingmarginwas45.0percent. Netinterestexpensewas$454mi11ion. OnaGAAPbasis,thetaxrateinthequarterwas49.3percent.Theadjustedtaxratewas13.7percent. Di1utedEPSinthefirstquarterwas$0.13onaGAAPbasis.Adjusteddi1utedEPS,exc1udingspecifieditems,was$2.46.Theseresu1tsinc1udeanunfavorab1eimpactof$0.08persharere1atedtoacquiredIPR&Dandmi1estonesexpe